EUVIMEDEUVIMED entdecken
Open Access

Early evaluation of severe immune checkpoint inhibitor-associated myocarditis: a real-world clinical practice

Xin Tang, Yuan Li, He Huang, Rui Shi, Li-Ting Shen, Wen-Lei Qian, Zhi-Gang Yang

Journal of Cancer Research and Clinical Oncology · 2023

DOI: 10.1007/s00432-023-04782-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cancer Research and Clinical Oncology, 2023. Verfasst von Xin Tang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Functional and Molecular Imaging Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu, Sichu…. Hauptthemen laut MEDLINE: Myocarditis, Antineoplastic Agents, Immunological, Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Natural Science Foundation of Sichuan Province, National Natural Science Foundation of China, 1·3·5 project for disciplines of excellence of West China Hospital, Sichuan University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Immune checkpoint inhibitor (ICI)-associated myocarditis is a rare but severe complication for patients treated with immunotherapy. This study aims to explore the predictive significance of patients' clinical features and examination results for the severity of ICI-associated myocarditis. METHODS: Data from a real-world cohort of 81 cancer patients who developed ICI-associated myocarditis after immunotherapy were retrospectively analyzed. The development of myocarditis of Common Terminology Criteria for Adverse Events (CTCAE) grades 3-5 and/or the major adverse cardiovascular event (MACE) was set as endpoints. Logistic regression was used to evaluate the predictive value of each factor. RESULTS: CTCAE grades 3-5 and MACE developed in 43/81 (53.1%) and 28/81 (34.6%) cases, respectively. The likelihood of CTCAE grades 3-5 and MACE increased with the accumulation of organs affected by the ICI-associated adverse events and initial clinical symptoms. Concurrent systematic therapies during ICI treatment did not raise the risk of myocarditis severity, while prior chemotherapy did. Besides classical serum cardiac markers, a higher neutrophil ratio was also related to poorer cardiac outcomes, whereas higher lymphocyte and monocyte ratios were predictors of favorable cardiac outcomes. The CD4+ T cell ratio and CD4/CD8 ratio were negatively related to CTCAE grades 3-5. Several cardiovascular magnetic resonance parameters were associated with myocarditis severity, whereas the predictive value of echocardiography and electrocardiogram was weak. CONCLUSION: This study comprehensively evaluated the prognostic value of patients' clinical characteristics and examination results and identified several predictors of severe ICI-associated myocarditis, which will facilitate early detection of severe ICI-associated myocarditis in patients receiving immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MyocarditisAntineoplastic Agents, ImmunologicalNeoplasmsHumansImmune Checkpoint InhibitorsRetrospective Studies

Stichwörter der Autor:innen

CTCAE gradingICI-associated myocarditisImmune checkpoint inhibitorsMACEPrognostic analysis

Substanzen

Immune Checkpoint InhibitorsAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Radiology, Functional and Molecular Imaging Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • Department of Cardiology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • Department of Radiology, Functional and Molecular Imaging Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu, Sichuan, China. yangzg666@163.com.

Förderung

  • Natural Science Foundation of Sichuan Province
  • National Natural Science Foundation of China
  • 1·3·5 project for disciplines of excellence of West China Hospital, Sichuan University

Zitieren

APA

Tang, X., Li, Y., Huang, H., Shi, R., Shen, L. T., Qian, W. L., & Yang, Z. G. (2023). Early evaluation of severe immune checkpoint inhibitor-associated myocarditis: a real-world clinical practice. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-023-04782-3

Vancouver

Tang X, Li Y, Huang H, Shi R, Shen LT, Qian WL, et al. Early evaluation of severe immune checkpoint inhibitor-associated myocarditis: a real-world clinical practice. Journal of Cancer Research and Clinical Oncology. 2023. doi:10.1007/s00432-023-04782-3

BibTeX
@article{Tang2023,
  author = {Tang, Xin and Li, Yuan and Huang, He and Shi, Rui and Shen, Li-Ting and Qian, Wen-Lei and Yang, Zhi-Gang},
  title = {Early evaluation of severe immune checkpoint inhibitor-associated myocarditis: a real-world clinical practice},
  journal = {Journal of Cancer Research and Clinical Oncology},
  year = {2023},
  doi = {10.1007/s00432-023-04782-3}
}
Kostenlos starten →